News & Updates

Large well-designed studies published in recent years point to an association of cerebral microbleeds (CMBs) with increased risks of intracerebral haemorrhage (ICH) and ischaemic stroke (IS). Although the association of CMBs with ICH is greater than with IS, the absolute incidence of IS is still higher than of ICH, implying that antithrombotics should not be routinely withheld for all patients with CMBs.

Cognitive changes in patients with chronic kidney disease (CKD) appear to correlate with accompanying changes in body mass index (BMI) and cerebral regional oxygen saturation (rSO2), reports a recent longitudinal study.

The combination of two targeted therapies, dabrafenib and trametinib, significantly improves the overall response rate (ORR) in paediatric patients with low-grade glioma (LGG) with BRAF V600 mutations compared with the combination of standard chemotherapy drugs, according to a study presented at ASCO 2022.

Some patients with benzodiazepine-refractory status epilepticus experience a toxin-related seizure, which can be successfully treated with a single dose of second-line antiseizure medication, according to a post hoc analysis of the Established Status Epilepticus Treatment Trial (ESETT).

The routine implementation of cerebral magnetic resonance imaging (cMRI) commonly detects low-grade abnormalities in extremely premature infants, such as low-grade intraventricular haemorrhage (IVH), white matter disease (WMD), and cerebellar injury (CBI), a new study has found.

Executive function (EF) in children appears to be linked to the metabolome, particularly with the amino acid leucine, higher levels of which seem to worsen EF and memory in this population, according to a recent Singapore study.

The use of oral contraceptive and hormone replacement therapy may put women at heightened risk of stroke, especially within the first year of use, possibly due to immediate changes in haemostatic balance, according to a study.

Patients with symptomatic internal carotid artery (ICA) stenosis may fare well with revacept, a competitive antagonist of glycoprotein VI, as the drug helps reduce the incidence of stroke or death, transient ischaemic attack, and bleeding complications, among others, according to a study.